HONG KONG – Increasingly concerned that the unchecked use of antibiotics is rapidly creating widespread resistance, regulators in Asia are developing stronger regulations and controls. Read More

Taiwan Liposome Co. Ltd., of Taipei, Taiwan, said its recruited 40 patients for its phase I/II trial of TLC599, with data readout expected in the second half of this year following the 12-week observation period. The study is testing TLC599, a new formulation entrapping a corticosteroid using TLC's sustained-release platform, Bioseizer, and administered as a local injection for treating osteoarthritis. Read More

SHANGHAI – Discovering and developing new drugs is hard anywhere in the world but perhaps especially so in China where it is a relatively new pursuit. For those who take on the challenge of bringing new drugs to market, now there is a place to share their woes and wisdom: the New Drug Founder's Club, or NDFC for short. Read More

TOKYO – Takeda Pharmaceutical Co. Ltd. said its TAK-214 vaccine, the world's first to tackle the norovirus, is now in phase IIb field efficacy trials. Read More

SHANGHAI – A transdermal pain patch being studied by Frontier Biotechnologies Inc., of Nanjing, China, has met its primary endpoints in a U.S. phase II trial of 146 patients with chronic lower back pain. The super-thin patch – only 200 micrometers thick – was designed to overcome safety issues common in prescription-strength painkillers for chronic pain. Read More

HONG KONG – Dendritic cell-based vaccine strategies that target cancer stem cells (CSCs) may be most effective when they are used in the adjuvant setting, according to findings of a new U.S./China collaborative preclinical study in mice reported in the June 20, 2016, early online edition of Cancer Research. Read More

NEW DELHI – Working with a U.S. partner, one of India's most active biopharma companies, Biocon Ltd., is moving forward on late-stage trials for a drug aimed at treating a common eye disorder for which there is no marketed treatment. Read More